32 results about "Pulmonary artery embolism" patented technology

A temporary inferior vena cava filter including a guidewire and a doublet cage filter distally located on the guidewire. The doublet cage filter has a proximal cage filter and a distal cage filter, both of resilient and biased toward their expanded or deployed state. The proximal and distal cage filters may be collapsed by actuation, preferably with a sheath. A method of protecting from pulmonary embolism during treatment of a deep vein thrombosis is disclosed. The doublet cage provides stability when deployed in the inferior vena cava, is readily retrieved and readily manufactured. A method of manufacturing the doublet cage filter assembly is also disclosed and involves a nitinol tube with plural cuts to form struts which are heat treated in an expanded state.

Aiming at the conditions that heparin has severe bleeding side effects in clinical practice and clinical application thereof is restricted, the invention discloses a technique for producing ultra-low molecular heparin sodium (calcium). The technique comprises the following steps of: taking heparin sodium solution, adding sodium nitrite solution for cracking; adjusting the lysis buffer by using alkaline; absorbing impurities by using an anion-exchange column; washing for obtaining ultra-low molecular heparin calcium; carrying out filtration by using an ultrafiltration membrane and obtaining a precipitate by using alcohol; and after desalting, dehydration, re-precipitation, cooling and drying, obtaining a finished product of ultra-low molecular heparin calcium. The product has better and safer antithrombotic effect under low level of anticoagulation, and can be widely used for preventing and treating diseases such as deep vein thrombosis, pulmonary embolism, disseminated intravascular coagulation, and the like.

Retrievable vena cava filters for the temporary or permanent prevention of Pulmonary embolism (PE) are disclosed. A filter in accordance with the present invention has a tube-within-tube structure with overlapping semi-spheres. The semi-spheres comprise a plurality of expandable legs. The first tube may have a plurality of slots allowing for deployment of a first or second sets of expandable legs on the second tube. The free end of each leg in the first set of expandable legs may be oriented in a direction the same as or opposite to the free end of each leg in the second set. The filter may also be formed from a single tube. In certain embodiments, the filter of the present invention can be retrieved from either end.

A device and method for intravascular treatment of an embolism, and particularly a pulmonary embolism, is disclosed herein. One aspect of the present technology, for example, is directed toward a clot treatment device that includes a support member having a plurality of first clot engagement members and second clot engagement members positioned about the circumference of a distal portion of the support member. In an undeployed state, individual first clot engagement members can be linear and have a first length, and individual second clot engagement members can be linear and have a second length that is less than the first length. The clot engagement members can be configured to penetrate clot material along an arcuate path and hold clot material to the clot treatment device.

The invention relates to the technical field of medical instruments, and discloses a net basket type thrombus removing device. The device comprises a far-end filtering disc, a near-end recycling discand at least one middle thrombus taking disc; the far-end filtering disc can be elastically expanded in the radial direction, and is provided with a net-shaped structure; the far-end filtering disc, the middle thrombus taking disc and the near-end recycling disc are sequentially and coaxially connected; in a natural unfolding state, the middle thrombus taking disc is in a flat disc shape; and thediameter of the middle thrombus taking disc is larger than that of the far-end filtering disc. According to the embodiment of the invention, a rapid, safe and effective thrombus removing mode can be provided for embolism treatment of pulmonary artery embolism and other large-size and thrombus-amount embolism, so that the treatment effect of acute middle-high risk pulmonary embolism patients can beimproved.

The invention discloses a N, N'-difluoro-substituted-phenyl derivative of 4-methoxyl-1, 3-phenyldiamide, and relative application, while the compound can restrain platelet aggregation activity, to treat the diseases as cardiac infarction, cerebrovascular disorder, pulmonary embolism and atherosclerosis, with antipyretic, analgesia, and antiphlogistic activities.

The present invention provides novel compositions and methods for the controlling appetite and weight and/or treating obesity using a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound. The invention also provides novel compositions and methods for treating or preventing disorders related to or complicated by excessive body weight or obesity, including coronary heart disease, osteoarthritis, osteoporosis, dislipidemias, gout, atherosclerosis, joint pain, sexual and fertility problems, respiratory problems, gall bladder disease, skin conditions, hypertension, diabetes, stroke, pulmonary embolism, sleep apnea, idiopathic intracranial hypertension, lower extremity venous stasis disease, gastro-esophageal reflux, urinary stress incontinence, metabolic syndrome, insulin resistance and cancer. The methods and compositions of the invention may employ a (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or related compound alone, or in combination with a second anti-appetite or anti-obesity agent.

The present invention provides novel proteins and peptides from the receptor binding region of human Growth Arrest Specific Gene 6 (Gas6) and antibodies, including specified portions or variants, specific for at least one such Gas6 peptide or fragment thereof. The aforesaid peptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-Gas6 antibodies. The invention also provides for the nucleic acids encoding such peptides and anti-Gas6 antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, including therapeutic formulations, administration and devices. Fifteen novel peptide sequences from the Gas6 G domain that are implicated in Gas6 interactions with its receptors are identified, isolated, and synthesized so as to allow generation of anti-Gas6 antibodies. The peptide sequences include three ESTs that encompass regions predicted to contribute to receptor binding or that can raise anti-Gas6 antibodies. This invention provides for such antibodies to be used in modulating or treating at least one Gas6-related disease in a cell, tissue, organ, animal, or patient. Such diseases may include, but are not limited to, thromboembolic disease, ischemic disease, venous thromboembolism, arterial or venous thrombosis, pulmonary embolism, restenosis, diabetic angiopathy and allograft atherosclerosis.

The present invention relates to a 5-amidino-2-hydroxybenzenesulfonamide derivative represented by the general formula:

wherein R¹ is an optionally substituted lower alkyl group, an optionally substituted lower alkoxy group, an optionally substituted lower alkenyl group, a cycloalkyl group or a lower acyl group etc.;

Q is a hydrogen atom or an optionally substituted lower alkyl group; and Z is a hydrogen atom or a hydroxy group etc., or a pharmaceutically acceptable salt thereof, which exert a potent and selective activated blood coagulation factor X inhibitory activity and is useful as an agent for the prevention or treatment of a disease occurred associating an activated blood coagulation factor X, a pharmaceutical composition comprising the same and an intermediate thereof. These compounds are useful as preventives or remedies for various diseases such as brain infarction, cerebral thrombosis, cerebral embolism, TIA, cerebral vascular jerk, Alzheimer's diseases, myocardial infarction, heart attack, heart failure, thrombosis, pulmonary infarction and pulmonary embolism.

The invention discloses a drug for treating pulmonary embolism and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The drug is prepared from the following raw materials: poria cocos, gynostemma pentaphylla, flos rosae rugosae, astragalus membranaceus, ginseng, toosendan fruit, radix curcumae, pseudo-ginseng, radix zanthoxyli, vinegar-processed corydalis tuber, angelica sinensis, agaric, fleece-flower root, rhizoma sparganii, curcuma zedoary, Chinese yam, rhizoma polygonati, radix paeoniae alba, liquorice, Chinese-date, glycerol and honey. The raw materials are respectively prepared into capsules and external cream, which are simultaneously used. The drug adopts pure natural Chinese herbal medicines, and is free of toxic and side effects, and accurate in curative effect; the pulmonary embolism can be more effectively treated; the preparation method is simple and convenient; the drug is simultaneously taken orally and used externally in the using method, so as to achieve a better effect.

Cava-Right Atrium Stent Graft for Functional Correction of Tricuspid Regurgitation. A vena cava-right atrium covered stent that connects the superior and inferior vena cava and the right atrium as a whole and is inserted through a percutaneous catheter. Both ends are adapted to the superior and inferior vena cava to form an inflow channel; the middle part is enlarged to adapt to the right atrium to form a blood storage pool. There is a filter screen to prevent pulmonary embolism in the blood discharge port of the stent, and a one-way diversion valve on the outside. During diastole, the negative pressure in the right atrium and the room pushes the blood away from the one-way guide valve of the blood outlet to enter the right atrium and right ventricle; during systole, the positive pressure of the right atrium and the room makes the one-way guide valve of the blood outlet close , to prevent backflow of blood into the stent graft. In the accompanying drawings, 1. The opening of the superior vena cava of the stent, 2. The crown of the covered stent, 3. The body of the superior vena cava of the covered stent, 4. The memory alloy wire of the covered stent, 5. The right atrium body of the covered stent (blood pool ), 6. Covered stent blood outlet and anti-embolism filter, 7. One-way diversion valve, 8. Covered stent inferior vena cava body, 9. Stent inferior vena cava opening.

The invention relates to a thrombus extraction device for pulmonary artery embolism. The thrombus extraction device comprises a thrombus extraction net rack; the thrombus extraction net rack is connected with the left end of a pushing guide wire through welding; the right end of the pushing guide wire is arranged on a guide wire twister; the pushing guide wire is sleeved with a micro catheter in a sliding mode; the micro catheter is sleeved with a middle catheter in a sliding mode; the middle catheter is sleeved with a guide catheter in a sliding mode; the micro catheter is connected with a first Y-shaped connector through a Luer taper; the middle catheter is connected with a second Y-shaped connector through a Luer taper; the guide catheter is connected with a third Y-shaped connector through a Luer taper; the guide catheter is connected with a first injector through a three-way valve and the third Y-shaped connector; the middle catheter is connected with a second injector through the three-way valve and the second Y-shaped connector; and a thrombus extraction net rack protective sleeve is arranged on the thrombus extraction net rack in a sleeving mode. According to the thrombus extraction device, the thrombus extraction device can be better matched with a blood vessel in size and more firmly embedded with thrombus, and newly-formed acute and old thrombus can be taken out.

The invention discloses thrombolytic effect of akebiasaponin D and the application thereof. The discovery of the thrombolytic activity of akebiasaponin D has innovativeness. Through anti-mouse pulmonary embolism and anti-rat carotid thrombus formation assay, SAD in vivo thrombolytic activity is researched. The thrombolytic effect has an obvious application prospect in the treatment of thrombotic diseases.

The invention is applied to the technical field of medical apparatus and instruments and discloses a vena cava filter. The vena cava filter can be temporarily or permanently placed in blood vessels for capturing thrombus and preventing pulmonary artery embolism. The vena cava filter comprises a blood vessel wall fixer for supporting in the blood vessels and a thrombus filter for capturing the thrombus; a fixing structure for positioning and fixing a supporting position of the blood vessel wall fixer is arranged on the blood vessel wall fixer; the thrombus filter is connected onto the blood vessel wall fixer; a releasing/recovering device for being connected with a control machine is arranged on the thrombus filter and/or the blood vessel wall fixer. The vena cava filter provided by the invention has the advantages of small contact area between the vena cava filter and blood vessel walls, convenience in operation, high capturing rate of the thrombus and long recovery time; the reliability and the safety of vena cava filter use are improved.

The invention discloses a novel pulmonary artery thrombectomy device which comprises a storage box, wherein a storage battery is fixedly connected to the right end of the bottom of an inner cavity of the storage box, two output ends of the storage battery are connected with a first motor and a second motor through wires respectively, and an output shaft of the first motor is connected with a first connecting disc through a first spring driving rod; a first top seat is arranged on the outer side of the first connecting disc, and the right side of the first connecting disc is movably connected with a connecting cylinder through a bearing. According to the invention, by means of a second motor, a second spring driving rod, a second connecting disc, a crushing rod and a second top seat, the purpose of effectively crushing the pulmonary artery embolism can be achieved, a first motor, a first spring driving rod, a first connecting disc, a connecting cylinder, a grabbing rod and a first top seat are arranged, and the grabbing rod can remove all the crushed pulmonary artery embolism; therefore, through cooperation of the structures, the treatment effect of the device is effectively improved, and therefore pulmonary artery embolism can be effectively eradicated.

The invention provides an application of radix ophiopogonis sapogenin in the preparation of medicine for tissue factor mediated diseases. The radix ophiopogonis sapogenin is used for preparing medicine for resisting thrombus, treating pulmonary embolism and acute lung injury, resisting atherosclerosis and preventing tumor angiogenesis. According to the invention, the radix ophiopogonis sapogenin realizes a remarkable inhibitory effect on TNF-alpha induced HUVECs cell tissue factor and can be used for preparing medicine for tissue factor mediated diseases.